47 search results for: mechanism of disease

The Benefits <b>of</b> Early Intervention in Reducing the Burden <b>of</b> <b>Disease</b> in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

Coexisting Type 2 Inflammatory <b>Disease</b>s Can Add to the Patient Overall <b>Disease</b> Burden
Type 2 Inflammation
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares highlights how patients with type 2 inflammatory diseases often experience multimorbidities, with overlapping symptoms that amplify their overall disease burden and impact quality of life.

View more
Which Biomarkers <b>of</b> AD Might Be Robust Enough to Be Evaluated as a Measure <b>of</b> <b>Disease</b> Modification?
Dermatology
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.

View more
Shared and Distinct: The Role <b>of</b> Type 2 Inflammation in Skin <b>Disease</b>s
Dermatology
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
expert video

Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively. 

View more
ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>
Dermatology
ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Podcast

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

View more
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional <b>Disease</b> Burden
Dermatology
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
expert video

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

View more
How Biologic Therapy May Lead to <b>Disease</b> Modification in Infants and Children With Atopic Dermatitis
Dermatology
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
expert video

This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.

View more
Both Clinical and Subclinical <b>Disease</b> Control Are Important to Achieve <b>Disease</b> Modification in AD
Dermatology
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.

View more
How Does Type 2 Inflammation Manifest in Chronic <b>Disease</b>s Across Different Organs?
Type 2 Inflammation
How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares discusses how type 2 inflammation plays a critical role in a broad range of diseases across different organ systems.

View more
In Chronic Pruritic Skin <b>Disease</b>s, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
Type 2 Inflammation
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim describes the dynamic neuroimmune interactions in chronic pruritic skin diseases, emphasizing how type 2 cytokines and sensory nerves actively influence both itch perception and tissue inflammation.

View more
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
Dermatology
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients
expert video

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.

View more
Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
Dermatology
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

View more